Center for Scientific Review; Notice of Closed Meetings, 73796-73797 [2015-29940]
Download as PDF
<![CDATA[
tkelley on DSK3SPTVN1PROD with NOTICES
73796
Federal Register / Vol. 80, No. 227 / Wednesday, November 25, 2015 / Notices
D., et al. (2015). HIV-positive-to-HIVpositive kidney transplantation—results
at 3 to 5 years. New England Journal of
Medicine, 372:613–20.
Neuhaus, J., Angus, B., Kowalska, J. D., et al.
(2010). Risk of all-cause mortality
associated with nonfatal AIDS and
serious non-AIDS events among adults
infected with HIV. AIDS, 24(5), 697–706.
OPTN Policies and Bylaws. From https://
optn.transplant.hrsa.gov/
policiesandbylaws/policies.asp.
Pais, R. & Benhamou, Y. (2010). Long-term
therapy for chronic hepatitis B in HIV
´
co-infected patients. Gastroenterologie
Clinique et Biologique, 34, 136–41.
Parsa, A., Kao, W. H. L., Xie, D., et al, (2013).
APOL1 risk variants, race, and
progression of chronic kidney disease.
New England Journal of Medicine,
369:2183–96.
Panel on Opportunistic Infections in HIVInfected Adults and Adolescents.
Guidelines for the prevention and
treatment of opportunistic infections in
HIV-infected adults and adolescents;
recommendations from the Centers for
Disease Control and Prevention, the
National Institutes of Health, and the
HIV Medicine Association of the
Infectious Diseases Society of America.
Available at https://aidsinfo.nih.gov/
contentfiles/lvguidelines/adult_oi.pdf.
(Accessed September 2015).
Pelletier S. J., Norman S. P., Christensen L.
L., et al. (2004). Review of
transplantation in HIV patients during
the HAART era. Clinical
Transplantation, 63–82.
Petrosillo, N., Chinello, P., & Cicalini, S.
(2006). Pulmonary hypertension in
individuals with HIV infection. AIDS,
20, 2128.
Prevention, C. f. D. C. a. (2013). HIV
Surveillance Supplemental Report.
Ragni, M. V., Dodson, S. F., Hunt, S. C., et
al. (1999). Liver transplantation in a
hemophilia patient with acquired
immunodeficiency syndrome. Blood, 93,
1113–1114.
Redd A. D., Quinn T. C., Tobian A. A. (2013).
Frequency and implications of HIV
superinfection. The Lancet Infectious
Diseases, 13(7), 622–628.
Reeves-Daniel, A. M., DePalma, J. A., Bleyer,
A. J., Rocco, M. V., Murea, M., Adams,
P. L., et al. (2011). The APOL1 Gene and
Allograft Survival after Transplantation.
American Journal of Transplantation,
11(5), 1025–1030.
Richterman, A., Blumberg, E., (2015). The
challenges and promise of HIV-infected
donors for solid organ transplantation.
Current Infectious Disease Reports, 17:1–
8.
Richterman, A., Sawinski, D., Reese, P.P., et
al, (2015). An assessment of HIV-infected
patients dying in care for deceased organ
donation in a United States urban center.
American Journal of Transplantation,
15:2105–2116.
Riella, L.V., Sheridan, A.M., (2015). Testing
for high-risk APOL1 alleles in potential
living kidney donors. American Journal
of Kidney Disease, (in press).
Roland, M., Carlson, L., & Stock, P. (2002).
VerDate Sep<11>2014
19:15 Nov 24, 2015
Jkt 238001
Solid organ transplantation in HIVinfected individuals. AIDS Clinical Care,
14(7), 59–63.
Roland, M. E., Adey, D., Carlson, L. L., &
Terrault, N. A. (2003a). Kidney and liver
transplantation in HIV-infected patients:
case presentations and review. AIDS
Patient Care STDS, 17(10), 501–507.
Roland, M. E., Lo, B., Braff, J., & Stock, P. G.
(2003b). Key clinical, ethical, and policy
issues in the evaluation of the safety and
effectiveness of solid organ
transplantation in HIV-infected patients.
Archives of Internal Medicine, 163(15),
1773–1778.
Roland, M. E., & Stock, P. G. (2003c). Review
of solid-organ transplantation in HIVinfected patients. Transplantation, 75(4),
425–429.
Sawinski, D., Goldberg, D. S., Blumberg, E.,
et al. (2015) Beyond the NIH multicenter
HIV transplant trial experience:
Outcomes of HIV+ liver transplant
recipients compared to HCV+ or HIV+/
HCV+ coinfected recipients in the
United States. Clinical Infectious
Disease, (in Press).
Sherman, K. E., Thomas, D., & Chung, R. T.
(2014). Human immunodeficiency virus
and liver disease forum 2012.
Hepatology, 59(1), 307–317.
´
Sims, D. B., Uriel, N., Gonzalez-Costello, J.,
et al. (2011). Human immunodeficiency
virus infection and left ventricular assist
devices: a case series. Journal of Heart
and Lung Transplantation, 30, 1060–
1064.
Soriano, V., Tuma, P., Labarga, P., et al.
(2009). Hepatitis B in HIV patients: what
is the current treatment and what are the
challenges? Journal of HIV Therapy,
14(1), 13–18.
Stock, P. G., Barin, B., Murphy, B., Hanto, D.,
Diego, J. M., Light, J., et al. (2010).
Outcomes of kidney transplantation in
HIV-infected recipients. New England
Journal of Medicine, 363(21), 2004–2014.
Taege, A. (2013). Organ transplantation and
HIV progress or success? A review of
current status. Curr Infectious Disease
Reports, 15, 67–76.
Tector, A. J., Mangu, R. S., Chestovich, P., et
al. (2006). Use of extended criteria livers
decreases wait time for liver
transplantation without adversity
impacting posttransplant survival.
Annals of Surgery, 244, 439–450.
Terrault, N. A., Roland, M. E., Schiano, T.,
Dove, L., Wong, M. T., Poordad, F., et al.
(2012). Outcomes of liver transplant
recipients with hepatitis C and human
immunodeficiency virus coinfection.
Liver Transplantation, 18(6), 716–726.
Touzot, M., Pillebout, E., Matignon, M.,
Tricot, L., Viard, J. P., Rondeau, E., et al.
(2010). Renal transplantation in HIVinfected patients: the Paris experience.
American Journal of Transplantation,
10(10), 2263–2269.
Uriel, N., Jorde, U. P., Cotarlan, V., et al.
(2009). Heart transplantation in human
immunodeficiency virus-positive
patients. Journal of Heart and Lung
Transplant, 28, 667–669.
Uriel, N., Nahumi, N., Colombo, P. C., et al.
(2014). Advance heart failure in patients
PO 00000
Frm 00099
Fmt 4703
Sfmt 4703
infected with human immunodeficiency
virus: is there equal access to care?
Journal of Heart and Lung
Transplantation (in press, online).
Wada, N., Jacobson, L. P., Cohen, M., French,
A., Phair, J., & Munoz, A. (2013). Causespecific life expectancies after 35 years
of age for human immunodeficiency
syndrome-infected and human
immunodeficiency syndrome-negative
individuals followed simultaneously in
long-term cohort studies, 1984–2008.
American Journal of Epidemiology,
177(2), 116–125.
Wada, N., Jacobson, L. P., Cohen, M., French,
A., Phair, J., & Munoz, A. (2014). Causespecific mortality among HIV-infected
individuals, by CD4 (+) cell count at
HAART initiation, compared with HIVuninfected individuals. AIDS, 28(2),
257–265.
Yoon, S. C., Hurst, F. P., Jindal, R. M.,
George, S. A., Neff, R. T., Agodoa, L. Y.,
et al. (2011). Trends in renal
transplantation in patients with human
immunodeficiency virus infection: an
analysis of the United States renal data
system. Transplantation, 91(8), 864–868.
Dated: November 20, 2015.
Francis S. Collins,
Director, National Institutes of Health.
[FR Doc. 2015–30172 Filed 11–24–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Reproductive Biology.
Date: December 8, 2015.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Michael Knecht, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
E:\FR\FM\25NON1.SGM
25NON1
Federal Register / Vol. 80, No. 227 / Wednesday, November 25, 2015 / Notices
Health, 6701 Rockledge Drive, Room 6176,
MSC 7892, Bethesda, MD 20892, (301) 435–
1046, knechtm@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Vascular
Biology and Hematology AREA.
Date: December 18, 2015.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Larry Pinkus, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4132,
MSC 7802, Bethesda, MD 20892, (301) 435–
1214, pinkusl@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 19, 2015.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–29940 Filed 11–24–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Amended Notice of Meeting
Notice is hereby given of a change in
the meeting of the NHLBI Institutional
Training Mechanism Review
Committee, December 11, 2015, 8:00
a.m. to December 11, 2015, 5:00 p.m.,
National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
which was published in the Federal
Register on November 12, 2015, 80 FR
69975.
This meeting is being amended
because the meeting will now start at 10
a.m. and will be conducted as a
teleconference. The meeting is closed to
the public.
Dated: November 19, 2015.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
tkelley on DSK3SPTVN1PROD with NOTICES
[FR Doc. 2015–29941 Filed 11–24–15; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
19:15 Nov 24, 2015
Jkt 238001
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Docket ID FEMA–2015–0001]
Changes in Flood Hazard
Determinations
Federal Emergency
Management Agency, DHS.
ACTION: Final notice.
AGENCY:
New or modified Base (1percent annual chance) Flood
Elevations (BFEs), base flood depths,
Special Flood Hazard Area (SFHA)
boundaries or zone designations, and/or
regulatory floodways (hereinafter
referred to as flood hazard
determinations) as shown on the
indicated Letter of Map Revision
(LOMR) for each of the communities
listed in the table below are finalized.
Each LOMR revises the Flood Insurance
Rate Maps (FIRMs), and in some cases
the Flood Insurance Study (FIS) reports,
currently in effect for the listed
communities. The flood hazard
determinations modified by each LOMR
will be used to calculate flood insurance
premium rates for new buildings and
their contents.
DATES: The effective date for each
LOMR is indicated in the table below.
ADDRESSES: Each LOMR is available for
inspection at both the respective
Community Map Repository address
listed in the table below and online
through the FEMA Map Service Center
at www.msc.fema.gov.
FOR FURTHER INFORMATION CONTACT: Luis
Rodriguez, Chief, Engineering
Management Branch, Federal Insurance
and Mitigation Administration, FEMA,
500 C Street SW., Washington, DC
20472, (202) 646–4064, or (email)
Luis.Rodriguez3@fema.dhs.gov; or visit
the FEMA Map Information eXchange
(FMIX) online at
www.floodmaps.fema.gov/fhm/fmx_
main.html.
SUPPLEMENTARY INFORMATION: The
Federal Emergency Management Agency
(FEMA) makes the final flood hazard
determinations as shown in the LOMRs
for each community listed in the table
below. Notice of these modified flood
hazard determinations has been
published in newspapers of local
circulation and 90 days have elapsed
SUMMARY:
PO 00000
Frm 00100
Fmt 4703
Sfmt 4703
73797
since that publication. The Deputy
Associate Administrator for Mitigation
has resolved any appeals resulting from
this notification.
The modified flood hazard
determinations are made pursuant to
section 206 of the Flood Disaster
Protection Act of 1973, 42 U.S.C. 4105,
and are in accordance with the National
Flood Insurance Act of 1968, 42 U.S.C.
4001 et seq., and with 44 CFR part 65.
For rating purposes, the currently
effective community number is shown
and must be used for all new policies
and renewals.
The new or modified flood hazard
information is the basis for the
floodplain management measures that
the community is required either to
adopt or to show evidence of being
already in effect in order to remain
qualified for participation in the
National Flood Insurance Program
(NFIP).
This new or modified flood hazard
information, together with the
floodplain management criteria required
by 44 CFR 60.3, are the minimum that
are required. They should not be
construed to mean that the community
must change any existing ordinances
that are more stringent in their
floodplain management requirements.
The community may at any time enact
stricter requirements of its own or
pursuant to policies established by other
Federal, State, or regional entities.
This new or modified flood hazard
determinations are used to meet the
floodplain management requirements of
the NFIP and also are used to calculate
the appropriate flood insurance
premium rates for new buildings, and
for the contents in those buildings. The
changes in flood hazard determinations
are in accordance with 44 CFR 65.4.
Interested lessees and owners of real
property are encouraged to review the
final flood hazard information available
at the address cited below for each
community or online through the FEMA
Map Service Center at
www.msc.fema.gov.
(Catalog of Federal Domestic Assistance No.
97.022, ‘‘Flood Insurance.’’)
Dated: October 30, 2015.
Roy E. Wright,
Deputy Associate Administrator for Insurance
and Mitigation, Department of Homeland
Security, Federal Emergency Management
Agency.
E:\FR\FM\25NON1.SGM
25NON1
]]>Agencies
[Federal Register Volume 80, Number 227 (Wednesday, November 25, 2015)]
[Notices]
[Pages 73796-73797]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-29940]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Reproductive Biology.
Date: December 8, 2015.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Michael Knecht, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
[[Page 73797]]
Health, 6701 Rockledge Drive, Room 6176, MSC 7892, Bethesda, MD
20892, (301) 435-1046, knechtm@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Vascular Biology and Hematology AREA.
Date: December 18, 2015.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Larry Pinkus, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 4132, MSC 7802, Bethesda, MD 20892, (301) 435-
1214, pinkusl@csr.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: November 19, 2015.
Carolyn Baum,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-29940 Filed 11-24-15; 8:45 am]
BILLING CODE 4140-01-P
